Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Royal Ancient Oats™ Studie (RAO)

16. november 2026 opdateret af: Standard Process Inc.

Effekten af Royal Ancient Oats™ på glykæmisk respons og fordøjelsesenzymer

Evaluating the effects of high avenanthramide ancient oat (Royal Ancient Oats™) muffins versus conventional oat muffins in regard to glycemic control.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is a randomized, two-period crossover trial with a run-in control baseline and repeated measures, designed to evaluate the effects of high avenanthramide ancient oat (Royal Ancient Oats™) muffins versus conventional oat muffins on glycemic control and related metabolic parameters. A total of 38 non-diabetic adults (HbA1c < 5.7%), who are either overweight (BMI 25-29.9) or obese (BMI ≥ 30) will start with a repeated measures baseline using regular flour (white wheat) muffins for three consecutive days. Following this, participants will be divided into two groups: 19 in the conventional oat muffin group and 19 in the Royal Ancient Oats™ muffin group. This sample size provides 90% power to detect a difference in AUC of at least 20% between treatments, with a two-sided alpha of 0.05.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

38

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • North Carolina
      • Kannapolis, North Carolina, Forenede Stater, 28081
        • Rekruttering
        • Standard Process Nutrition Innovation Center
        • Ledende efterforsker:
          • Chinmayee Panda, PhD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

35 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Non-diabetic (HbA1c<5.7%) adults both men and women between the ages of 35-65 years with body mass index (BMI) ranging from 25 to 30 kg/m2
  • Participants who meet the inclusion criteria will be screened prior to starting the study and must be able to adhere to the requirements of the study.
  • Willing to comply with study procedures and supplement regimens.
  • Providing consent to participate in the study.
  • Willing to limit/minimize foods that are rich sources of fiber and high carb content.
  • Participants should avoid taking any non-prescription/over-the-counter medications or nutritional supplements that could influence glycemic response. This includes vitamins, herbal supplements, and any medications affecting metabolism. Examples include probiotics and prebiotics, vit D, vit B12, Ginseng, fenugreek, weight loss supplements like green tea extract and Garcinia cambogia, fiber supplements like inulin and Psyllium husk. If participants need to make any changes due to health reasons, they should consult with the study coordinator before doing so.

Exclusion Criteria:

  • Participants who have experienced weight loss or gain exceeding 5% of their body weight in the past 3 months, including those involved in any weight loss or weight gain programs through diet and/or lifestyle changes.
  • Participants currently taking medications that could alter metabolism, such as weight loss medications, anti-hypertensive drugs, or lipid-lowering medications.
  • Participants with any chronic metabolic diseases, including diabetes, or those using supplements other than a daily multivitamin.
  • Pregnant or lactating women will be excluded from the study.
  • Participants who use tobacco products.
  • Participants who are unwilling to limit or minimize foods that are rich sources of fiber and high carbohydrate content.
  • Excessive alcohol consumption (e.g., more than two drinks per day for men and more than one drink per day for women)
  • Inconsistency in recent or planned changes in non-prescription/over-the-counter medications or nutritional supplements affecting glycemic response, including vitamins (e.g., Vitamin D, Vitamin B12), herbal supplements (e.g., Ginseng, Fenugreek), weight loss supplements (e.g., green tea extract, Garcinia cambogia), fiber supplements (e.g., inulin, psyllium husk), and probiotics/prebiotics.
  • Inability or unwillingness to maintain the current regimen of these medications and supplements throughout the study period without consulting the study coordinator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: A: Order of receiving muffins differs

A: Order of receiving muffins differs

muffins made with Royal Ancient Oat Flour™

Eksperimentel: B: Order of receiving muffins differs

B: Order of receiving muffins differs

muffins made with Royal Ancient Oat Flour™

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To compare the effect of consuming high avenanthramide Royal Ancient Oats™ muffins or conventional oat muffins versus white wheat flour muffins on postprandial glycemic response.
Tidsramme: 2 weeks

Area Under the Curve (AUC) for glucose levels over 24 hours, as measured by Continuous Glucose Monitoring (CGM).

2 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Tidsramme: 2 weeks

Subjective measures of hunger and satiety using Visual Analog Scales (VAS).

2 weeks
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Tidsramme: 2 weeks

Changes in GLP-1 levels (pg/mL)

2 weeks
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Tidsramme: 2 weeks

Changes in leptin (pg/mL)

2 weeks
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Tidsramme: 2 weeks

Changes in adiponectin (ng/mL)

2 weeks
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Tidsramme: 2 weeks

Changes in peptide YY (pg/mL)

2 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Tidsramme: 2 weeks

Changes in body weight (kilograms, kg) measured using a calibrated digital scale (InBody)

2 weeks
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Tidsramme: 2 weeks

Changes in waist circumference (centimeters, cm) measured using a flexible, non-stretchable measuring tape at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest.

2 weeks
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Tidsramme: 2 weeks

Changes in body fat percentage (%) as measured by bioelectrical impedance analysis (e.g., InBody).

2 weeks
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Tidsramme: 2 weeks

Changes in skeletal muscle mass (kg) as measured by bioelectrical impedance analysis (e.g., InBody).

2 weeks
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Tidsramme: 2 weeks

Changes in visceral fat level (arbitrary units) as measured by bioelectrical impedance analysis (e.g., InBody).

2 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. januar 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

15. september 2027

Datoer for studieregistrering

Først indsendt

13. januar 2026

Først indsendt, der opfyldte QC-kriterier

19. januar 2026

Først opslået (Faktiske)

28. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SP027

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .